Vyvanse Dosing Recommendations
Start Vyvanse at 30 mg once daily in the morning for patients aged 6 years and older with ADHD, then titrate by 10-20 mg weekly based on response and tolerability, with a target dose of 50-70 mg/day and a maximum of 70 mg/day. 1
Starting Dose
The FDA-approved starting dose is 30 mg once daily in the morning for both pediatric patients (≥6 years) and adults with ADHD 1. This differs from older immediate-release amphetamine formulations that traditionally started at 2.5 mg 2, but Vyvanse's prodrug design and extended-release properties necessitate this higher initial dose.
For patients aged 4-5 years (preschool), recent evidence suggests starting at lower doses (5-10 mg), though this remains off-label 3.
Titration Schedule
Increase by 10-20 mg weekly until optimal symptom control is achieved 1. The 2024 AJOG guideline specifically recommends 10 mg weekly increments 4, which aligns with the FDA label's flexibility of "10 mg or 20 mg weekly" 1.
Titration Algorithm:
- Week 1: 30 mg every morning
- Week 2: 40-50 mg if inadequate response
- Week 3: 50-60 mg if needed
- Week 4+: Up to 70 mg maximum
Monitor response using standardized ADHD rating scales from parents and teachers (or self-report in adults) at each dose adjustment 2. Contact can be maintained weekly by telephone during titration 2.
Target and Maximum Doses
- Target therapeutic range: 50-70 mg/day 1
- Maximum dose: 70 mg/day for all patients with normal renal function 1
- Renal impairment adjustments:
- Severe renal impairment (eGFR 15-29): Maximum 50 mg/day
- End-stage renal disease (eGFR <15): Maximum 30 mg/day 1
Key Differences from Traditional Amphetamines
Unlike immediate-release dextroamphetamine/amphetamine that requires 2-3 times daily dosing starting at 2.5-5 mg 2, Vyvanse is dosed once daily due to its prodrug design providing approximately 12-hour duration of action 5. The prodrug is converted to active dextroamphetamine through rate-limited enzymatic hydrolysis, creating a more gradual onset and potentially reduced abuse liability 6.
Clinical Monitoring
Before Starting:
- Baseline blood pressure, pulse, height, and weight 2
- Cardiac assessment to rule out structural heart disease 1
- Screen for contraindications: symptomatic cardiovascular disease, hyperthyroidism, glaucoma, active psychosis, or concurrent MOAI use 2
During Titration (Weekly):
- ADHD symptom ratings from multiple informants
- Systematic assessment of common adverse effects: decreased appetite, insomnia, irritability, headache, abdominal pain 7, 8
- Blood pressure and pulse monitoring
Maintenance Phase:
- Monthly visits until symptoms stabilized 2
- Quarterly blood pressure/pulse checks in adults 2
- Annual height/weight monitoring in children 2
Important Caveats
Stimulant-naïve patients may experience more adverse effects initially compared to those with prior stimulant exposure, particularly trouble sleeping, stomach pain, and decreased appetite 9. However, most adverse events are mild-to-moderate and occur predominantly in the first week of treatment 7.
Do not exceed 70 mg/day even if response is inadequate 1. If maximum dose fails to provide adequate symptom control, consider switching to an alternative stimulant formulation or adding behavioral interventions rather than further dose escalation 2. The principle "more is not necessarily better" applies—inadequate response at maximum dose suggests need for treatment strategy change, not higher dosing 2.
Appetite suppression and weight loss are dose-dependent and more pronounced with amphetamines than methylphenidate due to longer half-lives 2. Monitor weight at each visit as an objective measure 2.